Canberra, Australia
+919405476170
+919405476170
ANTI CANCER MEDICINE

Kixta 100mg Capsule (Palbociclib) — Ernest Oncology India Global Exporter | Supply to USA, UK, UAE, Australia, Singapore, Africa & Asia

In stock•cod not available
Phone Number

+919405476170

Mon-Thu: 10 AM - 2 PM • Fri: 3 PM - 7AM

Other Website Visit our other website
Address Canberra , Australian Capital Territory , Australia

Canberra, Australia, Australia, 1

Description

Kixta 100mg Capsule (Palbociclib): The Ultimate Global B2B Authority & Procurement Guide Kixta 100mg is a high-potency, targeted oncology medication manufactured by Zydus Lifesciences (Zydus Cadila). Containing the active ingredient Palbociclib, it is a key CDK4/6 inhibitor used in the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. For oncology wholesalers, hospital procurement heads, and international distributors across the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia, Kixta 100mg serves as a gold-standard Indian generic that provides a life-saving therapeutic option with significant cost-efficiency. As a premier pharmaceutical exporter from India, Ernest Oncology (a member of the Ernest Pharmaceutical Pvt. Ltd. group) manages the global distribution of Kixta 100mg, ensuring high-standard cold-chain logistics and full regulatory compliance. Understanding Kixta (Palbociclib) Kixta 100mg is an oral, reversible inhibitor of cyclin-dependent kinases (CDK) 4 and 6. These kinases are pivotal in the cell cycle, particularly in the transition from the growth phase to the DNA replication phase. Mechanism of Action: Interrupting Cancer Cell Division In many breast cancers, the CDK4/6 pathway is overactive, leading to the rapid and uncontrolled multiplication of cancer cells. Kixta works through a precise molecular blockade: Pathway Inhibition: Kixta targets the CDK4 and CDK6 enzymes, preventing them from pairing with Cyclin D. Rb Protein Phosphorylation: By blocking this complex, it prevents the phosphorylation of the Retinoblastoma (Rb) protein. Cell Cycle Arrest: Without Rb phosphorylation, the cancer cell is “locked“ in the G1 phase and cannot proceed to the S phase (DNA synthesis), effectively stopping tumor growth. Therapeutic Indications & Treatment Protocols Kixta 100mg is primarily indicated for the treatment of HR+/HER2- (Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative) advanced or metastatic breast cancer Combination Therapy Regimens With Aromatase Inhibitors: Used as initial endocrine-based therapy for postmenopausal women or men. With Fulvestrant: Used in patients whose disease has progressed following prior endocrine therapy. he Role of the 100mg Strength While 125mg is the standard starting dose, the 100mg capsule is essential for dose titration. It allows oncologists to manage treatment-emergent side effects (like neutropenia) by reducing the dosage without stopping the treatment entirely, ensuring the patient continues to benefit from the therapy. Administration, Dosage, & Storage Logistics Recommended Dosage Standards Schedule: One 100 mg capsule taken orally once daily for 21 consecutive days, followed by 7 days off treatment (a 28-day cycle). Administration: Kixta must be taken with food to ensure consistent absorption and plasma levels. Handling: Capsules must be swallowed whole. Do not crush, chew, or open them Global Storage & Shipping Integrity For B2B buyers in the Middle East (UAE, Saudi Arabia) and Asia (Singapore, Philippines), maintaining stability is critical: Temperature: Store at room temperature (20°C to 25°C / 68°F to 77°F). Protection: Keep in the original container to protect from light and moisture. Logistics: Ernest Oncology utilizes WHO-certified packaging to protect the product during international air freight, ensuring it arrives at its destination in peak clinical condition. Safety, Side Effects, & Clinical Monitoring Common Adverse Reactions Neutropenia: A decrease in white blood cell counts is the most common side effect (monitored via CBC). Fatigue: General tiredness. Infections: Increased susceptibility to common colds or respiratory infections. Nausea and Alopecia: Typically mild compared to traditional chemotherapy. Critical Monitoring Requirements Complete Blood Count (CBC): Monitored prior to the start of therapy and at the beginning of each cycle, as well as on Day 15 of the first two cycles. Liver Function: Periodic monitoring of LFTs is recommended. Ernest Oncology provides a complete regulatory package for every shipment to the USA, UK, Singapore, and Australia: Certificate of Analysis (COA): Verifying batch purity and potency. GMP Compliance: Ensuring Zydus Lifesciences meets the highest international manufacturing standards. Customs Documentation: Including COO (Certificate of Origin) and specialized for oncology medicines. Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Keywords

Other Products

view all

68179d65be22ee500d53ff54 Card 2

product image
ANTI CANCER MEDICINE

Ifosfamide Injection (500 mg, 1 g, 2 g) is a widely used cytotoxic medicine from the oxazaphosphorine group, indicated mainly for solid tumors and hematologic malignancies. Key strengths for procurement pages Ifosfamide Injection 500 mg Ifosfamide Injection 1 g Ifosfamide Injection 2 g Dosage forms: single‑dose vials, multi‑strength portfolio (500 mg, 1 g, 2 g) Typical pack configuration: 1 vial per carton, export‑grade secondary packaging Stability and transport: controlled temperature, light‑protected, compliant with standard cold‑chain or ambient logistics according to product specification Provide detailed specification sheets and COAs for regulatory authorities and institutional buyers to support product registration and tender submissions. Indications and Clinical Use Ifosfamide Injection is used in combination chemotherapy regimens for various malignancies, typically in specialist oncology units. As this is a YMYL (Your Money Your Life) pharmaceutical topic, content for public sites should stay informational and avoid therapeutic claims beyond approved labels. Safety, Handling, and Regulatory Compliance Ifosfamide Injection is intended for handling by trained oncology professionals using established safety procedures. International supplies are supported with quality certifications and export documentation based on destination country requirements. Product Specifications Feature Description Generic Name Ifosfamide Dosage Form Sterile Powder for Injection Available Strengths 500 mg, 1 g, 2 g Therapeutic Class Anticancer Medicine Drug Category Alkylating Agent Route Intravenous Administration Prescription Status Hospital Prescription Only Supply Type Bulk Supply & International Export Country of Origin India Clinical Uses: -Soft tissue sarcoma treatment protocols -Bone cancer management -Testicular cancer therapy -Lymphoma treatment plans -Advanced oncology care -Multi-drug chemotherapy programs Wholesale Ifosfamide Injection Supplier Ifosfamide 500 mg for Hospital Procurement Ifosfamide Injection 1 g Bulk Distributor Ifosfamide 2 g Global Pharmaceutical Supply Trusted Oncology Injectable Exporter Cancer Care Injection Supplier Worldwide Sterile Ifosfamide Injection Manufacturer Ifosfamide Oncology Medicine Distributor Bulk Chemotherapy Injection Supplier 🏥 Your Trusted Global Partner for Oncology Pharmaceuticals [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Export • Distribution • Bulk Supply 📲 WhatsApp: +91 9405476170 https://wa.me/message/V2MEXZ6ZAYY5B1 Frequently Asked Questions 1. Is Ifosfamide Injection supplied for international hospital procurement? Yes. Bulk quantities are available for licensed hospitals, oncology distributors, pharmaceutical importers, and government healthcare organizations. 2. Which strengths of Ifosfamide Injection are available? The commonly supplied strengths include 500 mg, 1 g, and 2 g, depending on manufacturer availability and destination market requirements. 3. How is Ifosfamide Injection administered? It is administered intravenously by qualified healthcare professionals in specialized oncology or hospital settings according to prescribed chemotherapy protocols. 4. What export documents are provided with international orders? Eligible shipments may include COA, COO, CPP (where applicable), commercial invoice, packing list, batch documents, and other regulatory paperwork required by the importing country. 5. Why do international buyers choose Indian exporters for Ifosfamide Injection? Indian pharmaceutical exporters are valued for their ability to provide consistent bulk availability, internationally accepted manufacturing standards, responsive export support, and efficient global distribution networks. This enables hospitals, oncology distributors, and licensed importers to maintain a dependable supply of quality injectable medicines while meeting their procurement and regulatory requirements. Cyclophosphamide Injection Doxorubicin Injection Cisplatin Injection Carboplatin Injection Gemcitabine Injection Etoposide Injection

68179d65be22ee500d53ff54 Card 2

product image
ANTI CANCER MEDICINE

About Imatinib Mesylate Tablets Imatinib Mesylate Tablets are prescription oncology medicines belonging to the tyrosine kinase inhibitor (TKI) class. They are widely used in specialized oncology and hematology treatment programs under the supervision of qualified medical professionals. The tablets are manufactured following stringent pharmaceutical quality standards and supplied to regulated healthcare markets through licensed distribution networks. Product Profile Specification: Information Generic Name: Imatinib Mesylate Dosage Form: Oral Tablets Available Strengths: 100 mg & 400 mg Therapeutic Category: Oncology Medicine Drug Class: :Tyrosine Kinase Inhibitor (TKI) Prescription Status: Prescription Only Country of Origin: India Medical Applications: Hematology treatment programs Oncology management protocols Long-term physician-supervised therapy Hospital cancer care services Specialized oncology clinics Clinical treatment pathways Safety & Clinical Guidance: Use the medicine only under medical supervision. Attend scheduled follow-up appointments. Inform healthcare providers about existing medical conditions and concurrent medications. Follow laboratory monitoring recommendations when advised. Report unusual symptoms promptly to the treating physician. Why Choose Our Pharmaceutical Export Services: Consistent international product availability Bulk supply for institutional buyers Experienced pharmaceutical export team Timely worldwide dispatch Complete export documentation support Quality-focused sourcing network Competitive commercial pricing Regulatory & Export Documentation Certificate of Analysis (COA) Certificate of Origin (COO) Commercial Invoice Packing List Batch Certificate Product Specification Sheet Manufacturing Compliance Docum Imatinib Mesylate Tablets 100 mg Imatinib Mesylate Tablets 400 mg Dasatinib Tablets Nilotinib Capsules Bosutinib Tablets Ponatinib Tablets Erlotinib Tablets Gefitinib Tablets Frequently Asked Questions 1. Which strengths of Imatinib Mesylate Tablets are available for export? The commonly supplied strengths are 100 mg and 400 mg, subject to manufacturer availability and destination market requirements. 2. Who can place bulk orders for Imatinib Mesylate Tablets? Licensed pharmaceutical importers, hospitals, oncology distributors, government procurement agencies, and authorized healthcare wholesalers can procure bulk quantities. 3. Are export documents provided with international shipments? Yes. Eligible orders can be accompanied by COA, COO, CPP (where applicable), commercial invoices, packing lists, batch documentation, and other required regulatory documents. 4. Which countries frequently source Imatinib Mesylate Tablets? Demand is strong in the United States (Washington, D.C.), United Kingdom (London), Australia (Canberra), Canada (Ottawa), Singapore, France (Paris), Germany (Berlin), UAE (Abu Dhabi), Saudi Arabia (Riyadh), South Africa (Pretoria), and Nigeria (Abuja). 5. Why do global healthcare buyers choose Indian exporters for Imatinib Mesylate Tablets? Indian pharmaceutical exporters are recognized for supplying quality-assured oncology medicines, dependable bulk availability, competitive commercial pricing, regulatory documentation support, and efficient worldwide distribution tailored to institutional healthcare procurement. #ImatinibMesylate #Imatinib100mg #Imatinib400mg #TyrosineKinaseInhibitor #TargetedTherapy #OncologyMedicine #CancerCare #PharmaceuticalExporter #WholesaleMedicines #HospitalPharmacy #MedicineSupplier #IndianPharma #BulkMedicine #HealthcareDistributor #GlobalHealthcare #MedicalImports #OncologyExport #HealthcareProcurement #CancerMedicineSupplier #ErnestPharmaceutical Online Imatinib Mesylate Tablets Imatinib Mesylate Tablets Supplier India Wholesale Imatinib Tablets Buy Imatinib 100 mg Tablets Imatinib 400 mg Tablet Exporter Tyrosine Kinase Inhibitor Supplier Oncology Tablet Export Company Bulk Cancer Medicine Supplier Pharmaceutical Exporter India 🏥 Your Trusted Global Partner for Oncology Pharmaceuticals [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Export • Distribution • Bulk Supply 📲 WhatsApp: +91 9405476170 https://wa.me/message/V2MEXZ6ZAYY5B1

68179d65be22ee500d53ff54 Card 2

product image
ANTI CANCER MEDICINE

Trusted Irinotecan Hydrochloride Injection Supplier from India for Global Pharmaceutical Distribution Irinotecan Hydrochloride Injection USP 20 mg/mL is a sterile prescription oncology medicine classified as a topoisomerase I inhibitor. It is administered by oncology specialists as part of carefully planned chemotherapy protocols in hospital and cancer treatment facilities. Every dose is prepared and infused under controlled clinical conditions to ensure safe administration and patient monitoring. Produced under internationally recognized manufacturing standards, this injectable medicine is supplied to regulated pharmaceutical markets through reliable global export channels. Medical Applications: Colorectal oncology care Gastrointestinal cancer management Advanced oncology treatment Combination chemotherapy protocols Hospital-based cancer therapy Specialist oncology services Safety, Handling & Regulatory Compliance: Irinotecan Injection should be prepared and administered by trained oncology personnel following institutional handling procedures. International shipments can be supported with GMP documentation, quality certificates, batch records, and regulatory documents required by destination markets. Administration Information: This injection is administered by qualified healthcare professionals through intravenous infusion in hospitals or oncology centres. The treatment schedule and dosage are determined according to the patient's clinical condition and approved chemotherapy protocol. Export Documentation Certificate of Analysis (COA) Certificate of Origin (COO) Certificate of Pharmaceutical Product (CPP) (where applicable) GMP Certificate Commercial Invoice Packing List Batch Manufacturing Documents Product Specification Sheet Worldwide Procurement of Injectable Oncology Medicines Continues to Expand The growing demand for advanced cancer treatment has increased procurement of injectable oncology medicines across international healthcare systems. Buyers from hospitals and pharmaceutical distribution companies continue seeking dependable exporters capable of delivering regulatory-compliant products, uninterrupted supply, and efficient worldwide logistics. Oxaliplatin Injection Fluorouracil Injection Leucovorin Calcium Injection Capecitabine Tablets Bevacizumab Injection Cetuximab Injection Gemcitabine Injection Frequently Asked Questions 1. Which strength of Irinotecan Injection is available for export? Irinotecan Hydrochloride Injection USP is commonly supplied as 20 mg/mL, with multiple vial presentations available depending on manufacturer specifications. 2. Who can purchase Irinotecan Injection in bulk? Licensed hospitals, oncology centres, pharmaceutical distributors, government procurement agencies, and authorized importers can place wholesale orders. 3. Is export documentation provided with international shipments? Yes. Eligible shipments may include COA, COO, GMP certificates, CPP (where applicable), commercial invoices, packing lists, and batch documentation. 4. Which countries frequently import Irinotecan Hydrochloride Injection? Major demand comes from the United States (Washington, D.C.), United Kingdom (London), Australia (Canberra), Canada (Ottawa), France (Paris), Germany (Berlin), Singapore, UAE (Abu Dhabi), Saudi Arabia (Riyadh), South Africa (Pretoria), and Nigeria (Abuja). 5. Why do international healthcare buyers source Irinotecan Injection from India? Indian pharmaceutical exporters are recognized for dependable manufacturing quality, strong export capabilities, regulatory documentation support, competitive commercial pricing, and reliable supply solutions for hospitals and healthcare distributors worldwide. Buy Irinotecan Hydrochloride Injection Online Irinotecan Injection USP 20 mg/mL Supplier Wholesale Irinotecan Injection Topoisomerase Inhibitor Supplier Oncology Injection Export Company Bulk Cancer Injection Supplier Injectable Oncology Medicine Export Pharmaceutical Exporter India 🏥 Your Trusted Global Partner for Oncology Pharmaceuticals [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Export • Distribution • Bulk Supply 📲 WhatsApp: +91 9405476170 https://wa.me/message/V2MEXZ6ZAYY5B1 #IrinotecanInjection #IrinotecanHydrochloride #OncologyInjection #CancerMedicine #Chemotherapy #InjectableMedicines #TopoisomeraseInhibitor #HospitalPharmacy #PharmaceuticalExporter #MedicineSupplier #IndianPharma #BulkMedicine #HealthcareDistributor #GlobalPharma #CancerCare #MedicalImports #OncologyExport #HospitalProcurement #WorldwideHealthcare #ErnestPharmaceutical